PMID- 29744858
OWN - NLM
STAT- MEDLINE
DCOM- 20190125
LR  - 20231115
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 143
IP  - 8
DP  - 2018 Oct 15
TI  - Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study 
      of competing risks and Type 2 diabetes mellitus.
PG  - 1868-1875
LID - 10.1002/ijc.31587 [doi]
AB  - Most previous studies of prostate cancer have not taken into account that men in 
      the studied populations are also at risk of competing event, and that these men 
      may have different susceptibility to prostate cancer risk. The aim of our study 
      was to investigate heterogeneity in risk of prostate cancer, using a recently 
      developed latent class regression method for competing risks. We further aimed to 
      elucidate the association between Type 2 diabetes mellitus (T2DM) and prostate 
      cancer risk, and to compare the results with conventional methods for survival 
      analysis. We analysed the risk of prostate cancer in 126,482 men from the 
      comparison cohort of the Prostate Cancer Data base Sweden (PCBaSe) 3.0. During a 
      mean follow-up of 6 years 6,036 men were diagnosed with prostate cancer and 
      22,393 men died. We detected heterogeneity in risk of prostate cancer with two 
      distinct latent classes in the study population. The smaller class included 9% of 
      the study population in which men had a higher risk of prostate cancer and the 
      risk was stronger associated with class membership than any of the covariates 
      included in the study. Moreover, we found no association between T2DM and risk of 
      prostate cancer after removal of the effect of informative censoring due to 
      competing risks. The recently developed latent class for competing risks method 
      could be used to provide new insights in precision medicine with the target to 
      classify individuals regarding different susceptibility to a particular disease, 
      reaction to a risk factor or response to treatment.
CI  - (c) 2018 The Authors. International Journal of Cancer published by John Wiley & 
      Sons Ltd on behalf of Union for International Cancer Control.
FAU - Haggstrom, Christel
AU  - Haggstrom C
AUID- ORCID: 0000-0001-6808-4405
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
AD  - Department of Biobank Research, Umea University, Umea, Sweden.
AD  - King's College London, School of Cancer and Pharmaceutical Sciences, 
      Translational Oncology & Urology Research (TOUR), London, United Kingdom.
FAU - Van Hemelrijck, Mieke
AU  - Van Hemelrijck M
AD  - King's College London, School of Cancer and Pharmaceutical Sciences, 
      Translational Oncology & Urology Research (TOUR), London, United Kingdom.
AD  - Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
FAU - Garmo, Hans
AU  - Garmo H
AD  - King's College London, School of Cancer and Pharmaceutical Sciences, 
      Translational Oncology & Urology Research (TOUR), London, United Kingdom.
AD  - Regional Cancer Centre Uppsala/Orebro, Uppsala, Sweden.
FAU - Robinson, David
AU  - Robinson D
AD  - Department of Urology, Ryhov Hospital, Jonkoping, Sweden.
FAU - Stattin, Par
AU  - Stattin P
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Rowley, Mark
AU  - Rowley M
AD  - Institute for Mathematical and Molecular Biomedicine, King's College London, 
      London, United Kingdom.
AD  - Saddle Point Science, London, United Kingdom.
FAU - Coolen, Anthony C C
AU  - Coolen ACC
AD  - Institute for Mathematical and Molecular Biomedicine, King's College London, 
      London, United Kingdom.
FAU - Holmberg, Lars
AU  - Holmberg L
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
AD  - King's College London, School of Cancer and Pharmaceutical Sciences, 
      Translational Oncology & Urology Research (TOUR), London, United Kingdom.
LA  - eng
GR  - MC_PC_15031/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180810
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/*etiology
MH  - Research Design
MH  - Risk Factors
MH  - Survival Analysis
MH  - Sweden
PMC - PMC6220128
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - competing risks
OT  - latent class
OT  - prostate cancer
OT  - survival analysis
EDAT- 2018/05/11 06:00
MHDA- 2019/01/27 06:00
PMCR- 2018/11/07
CRDT- 2018/05/11 06:00
PHST- 2017/11/22 00:00 [received]
PHST- 2018/04/13 00:00 [revised]
PHST- 2018/04/27 00:00 [accepted]
PHST- 2018/05/11 06:00 [pubmed]
PHST- 2019/01/27 06:00 [medline]
PHST- 2018/05/11 06:00 [entrez]
PHST- 2018/11/07 00:00 [pmc-release]
AID - IJC31587 [pii]
AID - 10.1002/ijc.31587 [doi]
PST - ppublish
SO  - Int J Cancer. 2018 Oct 15;143(8):1868-1875. doi: 10.1002/ijc.31587. Epub 2018 Aug 
      10.